Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | UBE2M | P61081 | 6/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950673 | 0.91 | CCR5 (0.50) | DRD2CCR5UBE2MDCUN1D1KMT2A | |
| SCHEMBL3542065 | 0.80 | KCNH2 (0.56) | DRD2CCR5UBE2MDCUN1D1KCNH2 | |
| SCHEMBL3532809 | 0.78 | DRD2 (0.49) | DRD2CCR5UBE2MDCUN1D1KCNH2 | |
| SCHEMBL3539247 | 0.77 | CCR5 (0.58) | DRD2CCR5UBE2MDCUN1D1KCNH2 | |
| SCHEMBL13800059 | 0.73 | OPRM1 (0.49) | DRD2KMT2AMEN1RAB9AKCNH2 | |
| Bamipine SCHEMBL29626 | 0.72 | KCNH2 (0.66) | DRD2CCR5KMT2AMEN1RAB9A | |
| Bamipine SCHEMBL4424873 | 0.71 | KCNH2 (0.64) | DRD2CCR5KMT2AMEN1RAB9A | |
| SCHEMBL13080536 | 0.70 | OPRM1 (0.54) | KMT2AMEN1RAB9AOPRM1 | |
| SCHEMBL5969537 | 0.70 | CCR5 (0.49) | DRD2CCR5UBE2MDCUN1D1KCNH2 | |
| SCHEMBL24538034 | 0.70 | OPRM1 (0.46) | DRD2KMT2AMEN1RAB9AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | DRD2 4178/4885CCR5 1541/4885UBE2M 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.